Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · IEX Real-Time Price · USD
21.00
+0.21 (1.01%)
Apr 23, 2024, 4:00 PM EDT - Market closed
Akero Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Akero Therapeutics stock have an average target of 44.25, with a low estimate of 30 and a high estimate of 60. The average target predicts an increase of 110.71% from the current stock price of 21.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AKRO stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Initiates $30 | Hold | Initiates | $30 | +42.86% | Apr 22, 2024 |
| UBS | UBS | Strong Buy Maintains $39 → $42 | Strong Buy | Maintains | $39 → $42 | +100.00% | Mar 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $43 → $50 | Strong Buy | Maintains | $43 → $50 | +138.10% | Mar 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $43 | Strong Buy | Maintains | $40 → $43 | +104.76% | Mar 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +90.48% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.05
from -2.89
EPS Next Year
-4.42
from -4.05
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 68.0M | 121.9M | 389.8M |
| Avg | n/a | n/a | 35.1M | 29.6M | 172.5M |
| Low | n/a | n/a | n/a | n/a | 61.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 247.4% | 1,217.0% |
| Avg | - | - | - | -15.6% | 482.8% |
| Low | - | - | - | - | 106.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.03 | -3.53 | -3.52 | -0.98 | 2.29 |
| Avg | -4.05 | -4.42 | -4.14 | -0.95 | 2.22 |
| Low | -5.00 | -5.29 | -4.77 | -0.91 | 2.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.